Alere announces cash dividend of $3.00 per share on Series B Convertible Perpetual Preferred Stock Alere Inc. , a worldwide leader in empowering individuals to take higher control of their wellness at home by connecting innovative diagnostics in the hands of individuals to their healthcare providers, has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock .The principal efficacy analysis was performed with data from the modified intention-to-treat population . A per-protocol analysis was also performed . Missing values due to patient death or withdrawal were imputed since defined in the Supplementary Appendix. For evaluation of the primary end point, a two-sided test at the 5 percent significance level for the difference in the procedure effect between your riociguat group and the placebo group was performed. The comparison was carried out by using analysis of covariance, with baseline value as a covariate and treatment group and area as main effects. The secondary efficacy variables were formally tested if the principal comparison was significant at a two-sided level of 5 percent. A hierarchical testing treatment was performed, with the variables in the following order: pulmonary vascular level of resistance, NT-proBNP level, WHO useful class, time to scientific worsening, Borg dyspnea score, EQ-5D score, and LPH questionnaire score .